Allergan’s SiRNA Treatment AGN-745 Will Likely Have Difficulty Gaining Market Share

Financial Times

Allergan’s AGN-745 will likely have difficulty gaining market share over Genentech’s Lucentis - and similar drug Avastin used off-label - in the treatment of wet-AMD, physicians told Pharmawire.